Dosage and administration of an Anti-ox40l antibody
Administering anti-OX40L antibodies in specific dosages and schedules addresses immune overactivation in inflammatory diseases by modulating T cell activity, providing effective treatment for conditions such as atopic dermatitis and asthma.
WO2025255353A1 Publication Date: 2025-12-11APOGEE THERAPEUTICS INC
39 Cites 1 Cited by
Patent Information
- Application Number
- PCT/US2025/032460
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-02-28
- Filing Date
- 2025-06-05
- Publication Date
- 2025-12-11
AI Technical Summary
Technical Problem
There is a need for improved therapeutics and methods of treatment that target OX40L to address immune overactivation in inflammatory conditions such as atopic dermatitis and asthma.
Method used
Administering an anti-OX40L antibody or its antigen binding fragment according to specific clinical dosage regimens, including doses of 75 mg, 150 mg, 300 mg, 600 mg, or 1200 mg, and dosing schedules such as every three or six months, to modulate T cell activity and regulate immune response.
Benefits of technology
The administration of anti-OX40L antibodies effectively targets OX40L, reducing immune overactivation and alleviating symptoms in inflammatory diseases like atopic dermatitis and asthma.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided are dosages and methods for clinical treatment of human patients using an anti-OX40L antibody, or antigen binding fragment thereof.
Need to check novelty before this filing date? Find Prior Art